Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

IRC-083927 is a new tubulin binder that inhibits growth of human tumor cells resistant to standard tubulin-binding agents.

Liberatore AM, Coulomb H, Pons D, Dutruel O, Kasprzyk PG, Carlson M, Nelson AS, Newman SP, Stengel C, Auvray P, Hesry V, Foll B, Narboux N, Morlais D, Le Moing M, Bernetiere S, Dellile R, Camara J, Ferrandis E, Bigg DC, Prévost GP.

Mol Cancer Ther. 2008 Aug;7(8):2426-34. doi: 10.1158/1535-7163.MCT-08-0208. Erratum in: Mol Cancer Ther. 2009 Jan;8(1):274.

2.

Synthesis and bioevaluation of 22-hydroxyacuminatine analogs.

Grillet F, Baumlová B, Prévost G, Constant JF, Chaumeron S, Bigg DC, Greene AE, Kanazawa A.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2143-6. doi: 10.1016/j.bmcl.2008.01.082. Epub 2008 Jan 30.

PMID:
18276141
3.

BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.

Demarquay D, Huchet M, Coulomb H, Lesueur-Ginot L, Lavergne O, Camara J, Kasprzyk PG, Prévost G, Bigg DC.

Cancer Res. 2004 Jul 15;64(14):4942-9.

4.

New method of synthesis of Vinca alkaloid derivatives.

Fahy J, Thillaye du Boullay V, Bigg DC.

Bioorg Med Chem Lett. 2002 Feb 11;12(3):505-7.

PMID:
11814829
5.

A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.

Bailly C, Laine W, Baldeyrou B, Demarquay D, Huchet M, Coulomb H, Lanco C, Lavergne O, Bigg DC.

Anticancer Drug Des. 2001 Feb;16(1):27-36.

PMID:
11762642
6.

Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60 cells.

Lansiaux A, Facompré M, Wattez N, Hildebrand MP, Bal C, Demarquay D, Lavergne O, Bigg DC, Bailly C.

Mol Pharmacol. 2001 Sep;60(3):450-61.

7.

Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells.

Larsen AK, Gilbert C, Chyzak G, Plisov SY, Naguibneva I, Lavergne O, Lesueur-Ginot L, Bigg DC.

Cancer Res. 2001 Apr 1;61(7):2961-7.

8.

The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison.

Demarquay D, Huchet M, Coulomb H, Lesueur-Ginot L, Lavergne O, Kasprzyk PG, Bailly C, Camara J, Bigg DC.

Anticancer Drugs. 2001 Jan;12(1):9-19.

PMID:
11272292
9.

Kinetics of in vitro hydrolysis of homocamptothecins as measured by fluorescence.

Chauvier D, Chourpa I, Bigg DC, Manfait M.

Ann N Y Acad Sci. 2000;922:314-6. No abstract available.

PMID:
11193910
10.

Homocamptothecins: E-ring modified CPT analogues.

Lavergne O, Demarquay D, Kasprzyk PG, Bigg DC.

Ann N Y Acad Sci. 2000;922:100-11. Review.

PMID:
11193885
11.

Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins.

Lavergne O, Demarquay D, Bailly C, Lanco C, Rolland A, Huchet M, Coulomb H, Muller N, Baroggi N, Camara J, Le Breton C, Manginot E, Cazaux JB, Bigg DC.

J Med Chem. 2000 Jun 1;43(11):2285-9.

PMID:
10841808
12.

Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.

Philippart P, Harper L, Chaboteaux C, Decaestecker C, Bronckart Y, Gordover L, Lesueur-Ginot L, Malonne H, Lavergne O, Bigg DC, da Costa PM, Kiss R.

Clin Cancer Res. 2000 Apr;6(4):1557-62.

13.

Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.

Bailly C, Lansiaux A, Dassonneville L, Demarquay D, Coulomb H, Huchet M, Lavergne O, Bigg DC.

Biochemistry. 1999 Nov 23;38(47):15556-63.

PMID:
10569939
14.

BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.

Lavergne O, Harnett J, Rolland A, Lanco C, Lesueur-Ginot L, Demarquay D, Huchet M, Coulomb H, Bigg DC.

Bioorg Med Chem Lett. 1999 Sep 6;9(17):2599-602.

PMID:
10498216
15.

Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties.

Lesueur-Ginot L, Demarquay D, Kiss R, Kasprzyk PG, Dassonneville L, Bailly C, Camara J, Lavergne O, Bigg DC.

Cancer Res. 1999 Jun 15;59(12):2939-43.

16.

[The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].

Lavergne O, Bigg DC.

Bull Cancer. 1998 Dec;Spec No:51-8. Review. French.

PMID:
9932086
17.

Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues.

Lavergne O, Lesueur-Ginot L, Pla Rodas F, Kasprzyk PG, Pommier J, Demarquay D, Prévost G, Ulibarri G, Rolland A, Schiano-Liberatore AM, Harnett J, Pons D, Camara J, Bigg DC.

J Med Chem. 1998 Dec 31;41(27):5410-9.

PMID:
9876111
18.

Flexible 1-[(2-aminoethoxy)alkyl]-3-ar(o)yl(thio)ureas as novel acetylcholinesterase inhibitors. Synthesis and biochemical evaluation.

Vidaluc JL, Calmel F, Bigg DC, Carilla E, Briley M.

J Med Chem. 1995 Jul 21;38(15):2969-73.

PMID:
7636858
19.
20.

Muscarinic agonists provide a new class of acaricide.

Bigg DC, Purvis SR.

Nature. 1976 Jul 15;262(5565):220-2. No abstract available.

PMID:
934339

Supplemental Content

Support Center